These biologic drugs offer a cost-effective alternative to original biologics, providing the same therapeutic benefits at lower prices. Regulatory pathways have streamlined approval processes, allowing for faster market entry of biosimilars. The growing familiarity and clinical confidence in biosimilars, along with supportive reimbursement policies, have driven their adoption across various therapeutic areas. This widespread product availability ensures more treatment options and improved access for patients, enhancing the overall healthcare landscape.
In An Emergency? Need Treatment?
In addition, we examine a subset of “specialty”drugs (as opposed to “traditional” or“non-specialty” drugs) and then focus on the top 10 percent ofdrugs based on price, i.e., “highest priced drugs”, most, butnot all, of which are specialty drugs. The highest priced drugs were definedon an annual basis, meaning the drugs change for each year of the sample.Table 1 definesthe types of drugs examined in this report. According to the WHO, in 2019, osteoarthritis affected approximately 528 million people globally.
The Germany Drugs Market Trends
TheIQVIA definition of specialty drug is different than the definition of a“specialty tier” in Part D. Another limitation relates to how we count the number of competitors – ourmethodology cannot adjust for the more nuanced effect of how large oraggressive a competitor may be. In our analysis, all competitors are treatedequally, so further research is warranted to examine whether different typesof market entrants result in a differential effect on the price and volumeof drugs sold. Finally, we define competition based on an active ingredient,rather than examining therapeutic competition, which would be a moreexpansive definition of competition. In the biological product market, the vast majority of products, 81percent, had only one manufacturer and these products accounted for74 percent of total revenues. It is important to note that there are arelatively small number of products in these latter categories, so asingle biological product can have a large impact on thispattern.
The increase in revenue from administering vaccines and providing telehealth services has led to an expansion of pharmacy services in the U.S. Pharmacies in the U.S. offers a variety of patient-care services and implement strategies to increase medication sales. According to the 2021 National Community Pharmacy Association (NCPA) Digest, pharmacies offer their customers a wide range of services.
- Cardiovascular therapies retained 22.50% of 2024 revenue on the back of entrenched prescription volumes for antihypertensives, statins, and antithrombotics.
- According to the Association for Accessible Medicines, approximately $2.9 trillion has been saved for patients and the U.S. healthcare system through the use of generics and biosimilars in the last decade.
- This has led major pharmaceutical companies to be constantly engaged in clinical trials for the development and, ultimately, the approvals of new products.
- These conditions are becoming more common, and corticosteroids are really good at helping people feel better.
- This resource offers a strategic and top-level summary for policymakers and decision-makers, to support the development and implementation of policies and actions in Europe, based on a robust understanding of the current drug landscape and emerging threats.
Pharmaceutical Processing Seals Global Market Report 2025
In 2019, 260 million Americans used OTC medications and made around 3 billion purchase visits. The COVID-19 pandemic has had a significant impact on the pharmacy market, with an increased demand for medications, vaccines, and other healthcare products. Pharmacies have played a critical role in the distribution of COVID-19 vaccines, and have also seen an increase in demand for telehealth services. In response to the pandemic, major pharmacy chains like Walmart, Walgreens Boots Alliance, CVS Health and Rite Aid have reported a sharp increase in demand for flu shots in their U.S. pharmacies in 2020, in some cases double from the previous year.
- The prevalence of colds, primarily caused by the rhinovirus, acts as a significant driver for the OTC drugs market.
- The most commonly used drug among the adult population includes lipid-lowering drugs, ACE inhibitors, analgesics, and antidepressants.
- Food and Drug Administration (FDA) has implemented programs to expedite the review and approval process for generic drugs, such as the Generic Drug User Fee Amendments (GDUFA).
- Disruptive innovations such as artificial intelligence (AI) in drug formulation, continuous manufacturing for enhanced efficiency, and digital platforms for direct-to-consumer distribution are becoming critical levers for competitive advantage.
- Moreover, the rapid adoption of automation technologies, such as robots, automated dispensing cabinets, and packaging systems, is driving the segment’s growth.
Report Scope
Although emerging technologies in drug delivery, comprising oral formulations of earlier parenteral drugs like GLP-1s, are optimizing patient access and adherence. Major companies operating in the pharmaceutical drug market are introducing innovative drugs such as Sohonos (palovarotene) capsules to gain a competitive edge in the market. Sohonos is a retinoid indicated for the reduction in volume of new heterotopic ossification in patients with fibrodysplasia ossificans progressiva (FOP). FOP is a rare genetic disorder of the connective tissue characterized by heterotopic ossification, which is the abnormal development of bone in areas of the body where bone is not normally present, such as the ligaments, tendons, and skeletal muscles.
SWOT Analysis Of Generic Drugs Market
The negative impacts of illicit drug markets are multifaceted and far-reaching, which is why they remain a key threat to the security of the European Union and the safety of its citizens. Healthcare leaders gathered at Health Evolution’s 2023 Connect to discuss important topics pertaining to the sector, including the pharmaceutical market’s critical obstacles. Leaders urged CEOs to use new AI technologies, pointing out that recent developments in AI might significantly affect pharmaceutical research and innovation. In general, leaders stressed the need for creative leadership to adopt new pharmaceutical advances and develop mechanisms that would guarantee the accessibility and affordability of upcoming therapies. This group is the largest and consumes various pharmaceutical products for better health and to improve quality of life.
Conclusion: COVID-19 Abates, Specialty Drugs Dominate, And Biosimilars Promise Growth
These behaviors collectively boost product turnover, reinforcing the position of cough and cold preparations as a primary driver in the nonprescription market. The convergence of immense opportunity from the patent cliff, disruptive technological innovation, and profound shifts in the global regulatory and geopolitical landscape will create a more complex, competitive, and dynamic industry than ever before. Stakeholders—from manufacturers to policymakers—must anticipate these changes and adapt their strategies to thrive in this new environment.
Moreover, the increase in the number of drugs prescribed by healthcare professionals for several disease treatments augments the segment share. By therapeutic application, the cardiovascular diseases segment is predicted to witness significant growth in the market over the forecast period. At present, around 620 million people worldwide are living with heart and circulatory diseases, and it is estimated that around 60 million new cases of cardiovascular diseases are reported annually.
Pharmaceutical drug refers to a substance created to treat, prevent, or cure an illness or other condition, or to lessen its symptoms. To list the most popular methods, drugs can be consumed orally, through a skin patch, by injection, or through an inhaler. Other vital medications made from natural materials include vaccinations, steroid hormones, human blood-plasma fractions, and antibiotics. Meet the challenge of changing stakeholder demands and increasing cost constraints with IQVIA’s integrated technology services and analytics-driven offerings.
Some address major health issues in large markets with growing patient populations, while others fill critical unmet treatment needs in smaller markets, providing much-needed hope for those living with relatively rare diseases that have few, if any, therapeutic options. Based on molecule type, the market for conventional drugs (small molecules) dominated with a revenue share of 54.7% in 2024. This growth can be attributed to a well-structured manufacturing facility, predictable pharmacokinetics, and oral bioavailability. Small molecules are anticipated to dominate the market as a technology, owing to a strong pipeline in which over two-thirds of the small molecule-based products are on accelerated pathways and are expected to enter the market in the upcoming years.
This makes them preferable incountries with underserved healthcare infrastructure and among low-incomepatients. Governments also provide significant subsidies for the production ofthese therapeutics, and insurance providers often prioritize pure generics tokeep premiums competitive. These are an exactcopy of branded drugs with the same dosage, active ingredients, andeffectiveness, making them a cost-effective option for patients and healthcareproviders in emerging economies, especially in Asia. Governments and insurancecompanies actively promote simple generics as part of cost-cutting measures inhealthcare expenditure.
